Hyperfine Launches Optive AI Software for Swoop MRI Systems

Hyperfine has launched Optive AI™ software for its Swoop® system, enhancing image quality through noise cancellation, image acquisition, reconstruction, and post-processing. The software is now commercially available in the US, FDA cleared, and also approved in Canada, Australia, and New Zealand. Existing customers can upgrade to the new software without hardware modifications, improving image quality for emergency, ICU, and outpatient neurology settings.

Hyperfine, Inc. (Nasdaq: HYPR), a leading health technology company, has announced the commercial launch of Optive AI™ software for its Swoop® system. This software enhances image quality through advanced noise cancellation, image acquisition, reconstruction, and post-processing techniques. The software is now commercially available in the U.S., having received FDA clearance, and is also approved for use in Canada, Australia, and New Zealand [1].

Optive AI™ software is compatible with existing Swoop® systems and requires no hardware modifications, allowing current users to immediately benefit from next-generation image quality. The software supports a wide range of patient populations and clinical use cases, including emergency, intensive care, and neurology office settings. The initial feedback from users has been positive, with significant improvements in image clarity and resolution, particularly in FLAIR images [1].

Jennifer Villa Frabizzio, MD, Chief of Neuroradiology at Jefferson Abington Hospital, noted that the upgrade has led to a marked improvement in image quality and speed. Similarly, Chetan Shah, MD, Chair of Pediatric Radiology at Wolfson Children’s Hospital, praised the software for its transformative impact on MRI technology, enabling portable MRI to extend beyond the ICU to serve ER patients and outpatients [1].

Maria Sainz, President and CEO of Hyperfine, stated, “We’re thrilled to bring the power of Optive AI™ software to our current customers. This is more than a software update—it’s a milestone that reflects our commitment to sustained innovation, improved clinical performance, and driving the adoption of portable brain MRI across multiple sites of care” [1].

Hyperfine's Swoop® Portable MRI Systems are FDA-cleared for brain imaging of patients of all ages and are designed for use in various clinical settings. The company's mission is to revolutionize patient care globally through accessible, clinically relevant diagnostic imaging [1].

References:

[1] https://www.stocktitan.net/news/HYPR/hyperfine-begins-commercial-launch-of-optive-aitm-software-bringing-skcjq5awvn39.html